Posted by: Thixia | April 21, 2008

Safety Information on RITUXAN (rituximab)

Health Canada

 

Advisory Regarding Rituxan

 

Safety Information on RITUXAN (rituximab)

 

 

The Health Products and Food Branch (HPFB) posts on the Health Canada web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.

This is duplicated text of a letter from Hoffmann-La Roche Ltd.
Contact the company for a copy of any references, attachments or enclosures.

 

PUBLIC COMMUNICATION
Health Canada Endorsed Important Safety Information on
RITUXAN (rituximab)


August 8, 2007

Subject:

Association of RITUXAN® (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) in patients with Systemic Lupus Erythematosus (SLE) and vasculitis

Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian healthcare professionals of important new safety information concerning RITUXAN (rituximab).

RITUXAN is authorized in Canada for the treatment of non-Hodgkin’s lymphoma (a cancer of the lymph nodes) and rheumatoid arthritis (an inflammatory disease of the joints).

Progressive Multifocal Leukoencephalopathy (PML)
PML is a rare and sometimes fatal disorder, caused by a virus which causes progressive damage or inflammation of the brain. It occurs almost exclusively in people with severe immune deficiency, who are more susceptible to disease.

Two (2) deaths from PML have been reported in patients with SLE treated with RITUXAN. Both of these patients had longstanding SLE and were given multiple courses of medications that suppress the immune system (the body’s system of defenses against disease) before receiving RITUXAN. One (1) case was also reported in a patient with vasculitis (inflammation of the blood vessels) treated with RITUXAN. This patient received multiple courses of medications that suppress the immune system before and during RITUXAN treatment. All cases occurred within 12 months of the last RITUXAN infusion and none of them occurred in Canada. A direct cause and effect between RITUXAN and these events has not been established, but cannot be ruled out.

PML has also been reported in patients with SLE or vasculitis receiving other medications that suppress the immune system without being given RITUXAN at the same time. Very rare cases (less than one case per 10,000 treated patients) have also been seen in patients with lymphoma receiving RITUXAN, although most of them were also receiving other medications that suppress the immune system.

In Canada, RITUXAN is not authorized for use in the treatment of patients with autoimmune diseases other than rheumatoid arthritis.

Hoffmann-La Roche Limited has sent a letter to healthcare professionals informing them of this new safety information. A copy of the healthcare professional letter and this communication are available on the Health Canada Website.

The prescribing information for RITUXAN has been revised to include more information on the cases of PML with RITUXAN.

Some examples of signs and symptoms of PML are:

• memory loss
• difficulty thinking, confusion
• loss of vision
• difficulty walking or speaking
• seizures
• loss of balance or coordination.

If you develop any of the above or any other unusual signs or symptoms, please contact your doctor or healthcare professional immediately.

Managing marketed health product-related adverse reactions depends on health-care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected adverse reactions in patients receiving RITUXAN should be reported to Hoffmann-La Roche Limited, or Health Canada at the following addresses:

Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, ON L5N 6L7
or call toll-free at 1-888-762-4388
or Fax at: 905-542-5864
or email to:
mississauga.drug_safety@roche.com
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866-234-2345
Fax: 866-678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel.: 613-954-6522
Fax: 613-952-7738

Sincerely,

Original signed by

Lorenzo Biondi
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: